Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts (Q39417407)

11 September 2017

1 reference

title

Pharmacotherapy of Glioblastoma: Established Treatments and Emerging Concepts (English)

1 reference

11 September 2017

0 references

1 reference

Enrico Franceschi

1

0 references

Alba A. Brandes

series ordinal

3

object named as

Alba A Brandes

1 reference

11 September 2017

Santino Minichillo

2

1 reference

11 September 2017

publication date

5 July 2017

1 reference

11 September 2017

1 reference

11 September 2017

volume

31

1 reference

11 September 2017

issue

8

1 reference

11 September 2017

page(s)

675-684

1 reference

Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Procarbazine, lomustine, and vincristine (PCV) chemotherapy for anaplastic astrocytoma: A retrospective review of radiation therapy oncology group protocols comparing survival with carmustine or PCV adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Bevacizumab for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine-DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Phase II Study of Radiotherapy and Temsirolimus versus Radiochemotherapy with Temozolomide in Patients with Newly Diagnosed Glioblastoma without MGMT Promoter Hypermethylation (EORTC 26082).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Targeted Therapeutics in Patients With High-Grade Gliomas: Past, Present, and Future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: correlation With MGMT promoter methylation status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Sex-specific clinicopathological significance of novel (Frizzled-7) and established (MGMT, IDH1) biomarkers in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Population pharmacokinetics of temozolomide in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Efficacy, pharmacology, and adverse effects of antiepileptic drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

P450 enzyme inducing and non-enzyme inducing antiepileptics in glioblastoma patients treated with standard chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Medical management of patients with brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Incidence and risk of thromboembolism during treatment of high-grade gliomas: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Corticosteroids in brain cancer patients: benefits and pitfalls

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Efficacy and tolerability of temozolomide in an alternating weekly regimen in patients with recurrent glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Dose dense 1 week on/1 week off temozolomide in recurrent glioma: a retrospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Phase 2 study of dose-intense temozolomide in recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

AVAREG: a phase II, randomized, noncomparative study of fotemustine or bevacizumab for patients with recurrent glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Early tumour shrinkage as a survival predictor in patients with recurrent glioblastoma treated with bevacizumab in the AVAREG randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Bevacizumab for the treatment of glioblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Phase II trial of lomustine plus temozolomide chemotherapy in addition to radiotherapy in newly diagnosed glioblastoma: UKT-03.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Alternating electric tumor treating fields for treatment of glioblastoma: rationale, preclinical, and clinical studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Structural and functional features of central nervous system lymphatic vessels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

CNS immune privilege: hiding in plain sight

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Hematogenous dissemination of glioblastoma multiforme.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Prospects of immune checkpoint modulators in the treatment of glioblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Issues in developing drugs for primary brain tumors: barriers and toxicities

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Immunotherapy at large: Balancing tumor immunity and inflammatory pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Immunotherapy coming of age: What will it take to make it standard of care for glioblastoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Immunotherapy response assessment in neuro-oncology: a report of the RANO working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine PET imaging for the detection of checkpoint inhibitor-related pseudoprogression in melanoma brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Vaccine-based immunotherapeutic approaches to gliomas and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Targetable signaling pathway mutations are associated with malignant phenotype in IDH-mutant gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

Extreme Vulnerability of IDH1 Mutant Cancers to NAD Depletion.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S40263-017-0454-8

T-lymphocyte entry into the central nervous system

21 January 2018

1 reference

12 December 2020

Pharmacokinetics and tumor localization of 131I-labeled anti-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies.

1 reference

12 December 2020

Future directions in the treatment of malignant gliomas with temozolomide.

1 reference

12 December 2020

Immunologically privileged sites

1 reference

12 December 2020

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO).

1 reference

12 December 2020

A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma

1 reference

12 December 2020

Pattern of care and effectiveness of treatment for glioblastoma patients in the real world: Results from a prospective population-based registry. Could survival differ in a high-volume center?

1 reference

12 December 2020

Bevacizumab for newly diagnosed glioblastoma

1 reference

12 December 2020

10.1007/S40263-017-0454-8

Identifiers

DOI

1 reference

11 September 2017

1 reference